In the PSMAfore trial, Pluvicto reduced the risk of radiographic progression or death by 59%. The Food and Drug Administration (FDA) has expanded the approval of Pluvicto ® (lutetium Lu 177 vipivotide ...
Metastatic ccRCC tumors with high PSMA gene expression have a high rate of angiogenesis, which may predict a better response to antiangiogenic therapies such as TKIs. Prostate-specific membrane ...
Prognosis in metastatic renal cell cancer (mRCC) with major venous involvement (MVI): A population-based study. This is an ASCO Meeting Abstract from the 2025 ASCO Genitourinary Cancers Symposium.
Effectiveness and safety of radium-223 in men with metastatic castration-resistant prostate cancer (mCRPC): A systematic literature review of 48 real-world studies. Median TTNT and OS by line of ...
In men with newly diagnosed metastatic hormone-sensitive prostate cancer, adding lutetium-177 PSMA-617 (177 Lu-PSMA-617) to standard hormone therapy led to a statistically significant improvement in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback